{'fraction_non_alphanumeric': 0.013182674199623353, 'fraction_numerical': 0.0, 'mean_word_length': 5.178294573643411, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Drugs in Blood and Brain

Conclusion The analytical method for the determination of NT in plasma here proved to be highly sensitive and specific. The method has been available for controlled trials and in clinical practice. Concerning the effect of TAs during long-term treatment our investigations have shed light on unclarified dosage factors of great importance for the elucidation of the possible prophylactic effect of the TAs. The plasma level determination of NT has simplified the discrimination between true pharmacological side effects, which call for reduction of dosage, and placebo or depressive symptoms. In patients not responding to a certain dosage, a plasma level determination will indicate whether the dosage should be raised or rather lowered. Our results prove this point, and we think we have a reasonable basis for the hypothesis that both a lower and an upper limit for therapeutic effect exist. Next, those patients who do not recover, even on optimal plasma levels, can be identified and receive alternative treatment, instead of undue prolongation of an ineffective therapy on changing doses. Whether a relationship between the plasma concentration and effects will hold also for other TAs remains to be investigated. It is not possible, at the present stage of knowledge, to extrapolate from one drug to another. It should also be pointed out that the curvilinear relationship between plasma level and therapeutic effect has only been demonstrated in patients with endogenous depressions and cannot be generalized to other depressive states without further trials.